Trials / Terminated
TerminatedNCT01687478
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine | Administered Orally |
| DRUG | Fluoxetine | Administered Orally |
| DRUG | Placebo | Administered Orally |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2012-09-19
- Last updated
- 2019-10-09
- Results posted
- 2017-08-24
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01687478. Inclusion in this directory is not an endorsement.